Aligos Therapeutics Inc. (ALGS): Price and Financial Metrics

Aligos Therapeutics Inc. (ALGS): $1.13

0.14 (+14.14%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ALGS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#129 of 360

in industry

ALGS Price/Volume Stats

Current price $1.13 52-week high $1.57
Prev. close $0.99 52-week low $0.54
Day low $0.98 Volume 690,100
Day high $1.15 Avg. volume 306,429
50-day MA $0.72 Dividend yield N/A
200-day MA $0.82 Market Cap 84.67M

ALGS Stock Price Chart Interactive Chart >

ALGS Stock Summary

  • ALIGOS THERAPEUTICS INC's stock had its IPO on October 16, 2020, making it an older stock than just 12.44% of US equities in our set.
  • Of note is the ratio of ALIGOS THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 13.75% of US stocks have a lower such ratio.
  • As for revenue growth, note that ALGS's revenue has grown 52.6% over the past 12 months; that beats the revenue growth of 91.34% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ALIGOS THERAPEUTICS INC, a group of peers worth examining would be RXRX, TSP, CRDF, CRIS, and BCYC.
  • ALGS's SEC filings can be seen here. And to visit ALIGOS THERAPEUTICS INC's official web site, go to www.aligos.com.

ALGS Valuation Summary

  • In comparison to the median Healthcare stock, ALGS's price/sales ratio is 36.36% higher, now standing at 3.
  • ALGS's price/sales ratio has moved NA NA over the prior 39 months.

Below are key valuation metrics over time for ALGS.

Stock Date P/S P/B P/E EV/EBIT
ALGS 2023-12-29 3.0 0.9 -0.6 0.1
ALGS 2023-12-28 3.0 0.9 -0.6 0.1
ALGS 2023-12-27 3.4 1.0 -0.7 0.0
ALGS 2023-12-26 3.4 1.0 -0.7 0.0
ALGS 2023-12-22 3.2 1.0 -0.6 0.1
ALGS 2023-12-21 3.2 1.0 -0.6 0.1

ALGS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALGS has a Quality Grade of D, ranking ahead of 21.18% of graded US stocks.
  • ALGS's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ALGS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -4.195
2020-12-31 0 NA -1.881

ALGS Price Target

For more insight on analysts targets of ALGS, see our ALGS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.67 Average Broker Recommendation 1.3 (Strong Buy)

Aligos Therapeutics Inc. (ALGS) Company Bio


Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.


ALGS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALGS Latest Social Stream


Loading social stream, please wait...

View Full ALGS Social Stream

Latest ALGS News From Around the Web

Below are the latest news stories about ALIGOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ALGS as an investment opportunity.

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from Dec

Yahoo | December 7, 2023

13 Stocks Insiders are Buying Now

In this article, we will take a look at the 13 stocks insiders are buying now. To see more such companies, go directly to 5 Stocks Insiders are Buying Now. With the end of 2023 now in sight, many can say with confidence that the much-dreaded recession everyone was talking about will not realize this […]

Yahoo | November 24, 2023

Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?

Aligos Therapeutics stock is falling alongside news of a secondary offering for ALGS that it won't see any proceeds of the sales from.

William White on InvestorPlace | November 20, 2023

Why Is Tharimmune (THAR) Stock Down 8% Today?

Tharimmune stock is falling after the company announced a reverse stock split for THAR shares that goes into effect later today.

William White on InvestorPlace | November 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning!

William White on InvestorPlace | November 20, 2023

Read More 'ALGS' Stories Here

ALGS Price Returns

1-mo 56.94%
3-mo 66.18%
6-mo 27.09%
1-year -25.17%
3-year -94.75%
5-year N/A
YTD 70.18%
2023 -30.32%
2022 -91.97%
2021 -57.07%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!